All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 22, 2022
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Global vaccine illustration

As COVID numbers drop, biopharma research remains steadfast

May 10, 2022
By Karen Carey
No Comments
For the first time since the early weeks of the COVID-19 pandemic in 2020, global deaths caused by the disease have fallen to their lowest point, as immunity against the SARS-CoV-2 virus and its variants continues to build. Infections and deaths appear to be decelerating, an optimistic sign that the pandemic may be nearing an end.
Read More
2022 MedCon

Cybersecurity expertise still in short supply, but solution nowhere in sight

May 9, 2022
By Mark McCarty
No Comments
Cybersecurity remains a pressing issue for medical technology, in part because there are new, small companies jumping into this space seemingly every day. However, there is a shortage of talent in cybersecurity, something that Dan Lyon, director of cybersecurity at Boston Scientific Corp., of Marlborough, Mass., said will not ease soon due to a lack of interest among colleges and universities in providing curriculum and degrees in this area.
Read More
Globe and currency symbols

At $18B so far, 2022 biopharma financings lag 2021 pace

May 9, 2022
By Karen Carey
No Comments
With 47% fewer biopharma financings than last year, investors who were once enthused over the industry’s potential in combatting the deadly SARS-CoV-2 virus appear to be taking a step back. So far in 2022, the industry has raised $18 billion across 346 financings through the first week of May. By the same time in 2021, it had raised three times that amount, $53.9 billion through 651 transactions.
Read More

Biggest gainers and losers for the week of May 2-6, 2022

May 6, 2022
No Comments
The top 10 biopharma stock gainers and losers for the week.
Read More

BioWorld and Nasdaq stock indices

May 6, 2022
No Comments
These graphs compare the performance of the biotech stocks for all of 2022 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.
Read More

Med-tech gainers and losers for May 2-6, 2022

May 6, 2022
No Comments
The top 10 med-tech stock gainers and losers for the week.
Read More

Biopharma money raised: Jan. 1-May 5, 2022

May 6, 2022
No Comments
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More
Hand holding IPO, financial icons

Biopharma money raised by month in 2022 (US$M)

May 6, 2022
No Comments
Biopharma money raised to-date and by month in 2022, including public, private and other financings.
Read More

Money raised by biopharma: 2022 vs. 2021 vs. 2020 vs. 2019

May 6, 2022
No Comments
Total raised in public, private and other financings of biopharma companies, comparing 2022 vs. 2021 vs. 2020 vs. 2019.
Read More

Med-tech M&As hit records in Q1 as deals continue to climb

May 5, 2022
By Karen Carey
No Comments
In sharp contrast with the biopharma industry, the med-tech industry has completed mergers and acquisitions worth a record amount in the first quarter of 2022, with the $63.7 billion combined value towering over every full year prior to 2021.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 127 128 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 20, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for May 20.
  • China U.S. deal

    Merck acquires global rights to cancer drug from Kelun in $1.4B deal

    BioWorld
    In a deal potentially worth more than $1.4 billion, Sichuan Kelun Pharmaceutical Co. Ltd. has out-licensed a large molecule drug in cancer to Merck & Co. Inc. for...
  • Hearing ear icon

    Cochlear to acquire rival Oticon Medical for $121M

    BioWorld MedTech
    Cochlear Ltd. will acquire Danish hearing implant company Oticon Medical A/S for AU$170 million (US$121 million) after parent company the Demant Group said it...
  • Illustration of cancer cells and immunotherapy treatment

    Former Genentech execs launch new immunotherapy biotech LTZ Therapeutics

    BioWorld
    After raising $17 million in seed funding, immunotherapy-focused biotech company, LTZ Therapeutics Inc., is announcing plans for the fledgling company whose...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing